Clinical Edge

Summaries of Must-Read Clinical Literature, Guidelines, and FDA Actions

Exosomal CA1 may predict chemotherapeutic efficacy in DLBCL

Key clinical point: Increased expression of exosomal carbonic anhydrase 1 was associated with poorer prognosis in DLBCL.

Major finding: Exosomal CA1 can promote chemotherapy resistance via the NF-kB and STAT3 pathways.

Study details: Exosomes were isolated from DLBCL patients and characterized by western blotting, dynamic light scattering and transmission electron microscopy.

Disclosures: The authors declared that they had no conflicts of interest.


"Exosomes are extracellular vesicles that contain protein and RNA and can be passed between cells. The role of exosomes in the disease process and response to therapy in lymphomas including diffuse large B-cell lymphoma (DLBCL) is not elucidated. Drs. Feng et al investigated exosomal contents from the serum of 112 DLBCL patients, and found that expression of carbonic anhydrase 1 was associated with chemoresistance. The authors conclude that this resistance occurs via the NF-kB and STAT3 pathways. While there is still much to be learned regarding exosomes in DLBCL, this research suggests a novel strategy by which prognosis could potentially be assessed in DLBCL patients followed by targeted therapeutic approaches in a clinical trial setting."

Sarah Rutherford, MD

Assistant Professor of Medicine, Weill Cornell Medicine

Dr. Rutherford has no relevant conflicts of interest.


Feng Y et al. Molecular Therapy: Nucleic Acids. 2020;